Description
PD-184352isananticancerchemotherapeuticMEK1/2andRafinhibitorthatisparticularlyeffectiveagainstcancersharboringB-RaforRASmutationssuchasV600E.PD-184352enhancesp53accumulationandcaspaseactivation,increaseslevelsofpro-apoptoticBimprotein,anddecreasinglevelsofcyclinD1,inducingcellcyclearrestandapoptosisinseveralcancercelllines.Thiscompoundalsoinducestumorregressioninanimalmodelscarryinglungtumors.
References
WickendenJA,JinH,JohnsonM,etal.ColorectalcancercellswiththeBRAF(V600E)mutationareaddictedtotheERK1/2pathwayforgrowthfactor-independentsurvivalandrepressionofBIM.Oncogene.2008Dec4;27(57):7150-61.PMID:18806830.
LunghiP,GiulianiN,MazzeraL,etal.TargetingMEK/MAPKsignaltransductionmodulepotentiatesATO-inducedapoptosisinmultiplemyelomacellsthroughmultiplesignalingpathways.Blood.2008Sep15;112(6):2450-62.PMID:18583568.
BainJ,PlaterL,ElliottM,etal.Theselectivityofproteinkinaseinhibitors:afurtherupdate.BiochemJ.2007Dec15;408(3):297-315.PMID:17850214.
JiH,WangZ,PereraSA,etal.MutationsinBRAFandKRASconvergeonactivationofthemitogen-activatedproteinkinasepathwayinlungcancermousemodels.CancerRes.2007May15;67(10):4933-9.PMID:17510423.
SquiresMS,NixonPM,CookSJ.Cell-cyclearrestbyPD184352requiresinhibitionofextracellularsignal-regulatedkinases(ERK)1/2butnotERK5/BMK1.BiochemJ.2002Sep1;366(Pt2):673-80.PMID:12069688.